I-mab Stock News

I-Mab (NASDAQ: IMAB ) has provided updates on the recent development relating to the Holding Foreign Companies Accountable Act (HFCAA) and its implementation. I-Mab is not on this list, and it has taken proactive measures in response. It has implemented additional business processes and control changes to meet the requirements outlined in the HFCAA, including engaging an accounting firm that is subject to … Full story available on Benzinga.com

I-Mab (NASDAQ: IMAB) has provided updates on the recent development relating to the Holding Foreign Companies Accountable Act (HFCAA) and its implementation.  I-Mab is not on this list, and it has t

Asana ASAN -26% on Q4 earnings release.ACM Research (ACMR) -17%.Sunshine Biopharma (SBFM) -16%.Revelation Biosciences (REVB) -15%.I-Mab (IMAB) -14%.Sentage Holdings (SNTG)…

The U.S. Food and Drug Administration granted orphan drug designation to I-Mab''s <> TJ-CD4B to treat gastric cancer including cancer of gastroesophageal junction.TJ-CD4B is part…

In the last trading session, 1.25 million shares of the I-Mab (NASDAQ:IMAB) were traded. Most recently the company’s share price was $27.82, and it changed around $2.93 or 11.77% from the last close, which brings the market valuation of the company to $2.36B. IMAB currently trades at a discount to its 52-week high of $85.40, … Why I-Mab (NASDAQ: IMAB) Stock Should Not Be Discarded By Investors In 2022 Read More »

I-Mab (NASDAQ:IMAB)s traded shares stood at 0.59 million during the last session. At the close of trading, the stocks price was $23.63, to imply a decrease of -5.67% or -$1.42 in intraday trading. The IMAB shares 52-week high remains $85.40, putting it -261.4% down since that peak but still an impressive 14.52% since price per After Sinking 4.33% During Past Week, Is I-Mab (NASDAQ: IMAB) Still A Buy? Read More »

I-Mab - ADR (IMAB) shares closed this week 36.0% lower than it did at the end of last week. The stock is currently down 55.9% year-to-date, down 57.6% over the past 12 months, and up 67.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.6%, and the S&P 500 fell 3.5%. Trading Activity Shares traded as high as $32.95 and as low as $20.81 this week.Trading volume this week was 75.9% higher than the 10-day average and 194.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 200.4% The company's stock price performance over the past 12 months lags the peer average by 74.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

I-Mab - ADR (IMAB) shares closed today 11.7% lower than it did at the end of yesterday. The stock is currently down 39.2% year-to-date, down 47.3% over the past 12 months, and up 130.6% over the past five years. Today, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 2.0%. Trading Activity Shares traded as high as $37.16 and as low as $28.27 this week.Shares closed 66.3% below its 52-week high and 1.9% above its 52-week low.Trading volume this week was 77.9% higher than the 10-day average and 172.7% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 306.9% The company's stock price performance over the past 12 months lags the peer average by 118.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

I-Mab - ADR (IMAB) shares closed today at 1.9% above its 52 week low of $28.27, giving the company a market cap of $2B. The stock is currently down 39.2% year-to-date, down 47.3% over the past 12 months, and up 130.6% over the past five years. This week, the Dow Jones Industrial Average fell 4.6%, and the S&P 500 fell 5.8%. Trading Activity Trading volume this week was 181.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 306.9% The company's stock price performance over the past 12 months lags the peer average by 118.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

I-Mab - ADR (IMAB) shares closed 0.7% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently down 25.3% year-to-date, down 30.5% over the past 12 months, and up 183.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 8.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 7.7% lower than its 5-day moving average, 19.2% lower than its 20-day moving average, and 41.4% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 328.7% The company's stock price performance over the past 12 months lags the peer average by 49.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

I-Mab''s (IMAB) senior management team has executed a share purchase plan.Founder, Chairman and acting CEO Jingwu Zang, President Andrew Zhu, Chief Financial Officer John Long,

I-Mab (IMAB) said the first patient was dosed in its China phase 2 study (NCT05145907) of efineptakin alfa (TJ107) in combination with Merck & Co

I-Mab (IMAB) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.